Clinical Trial Update: Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 substudy evaluating pembrolizumab alone or with investigational agents in melanoma brain metastases has completed. The update highlights safety and ef…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Melanoma | Phase 1, Phase 2 | Status: COMPLETED